Document is current
Any future updates will be listed below
-
Authors
Dubaissi, Eamon
Hilton, Emma N.
Lilley, Sarah
Collins, Richard
Holt, Charlotte
March, Peter
Danahay, Henry
Gosling, Martin
Grencis, Richard K
Roberts, Ian S
Thornton, David J https://orcid.org/0000-0001-7148-1970
-
Funding
Funding for this research was provided by:
National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC/S001034/1, NC/S001034/1, NC/S001034/1, NC/S001034/1, NC/S001034/1)
Biotechnology and Biological Sciences Research Council (IAA 403, BB/W006456/1, BB/W006456/1, BB/W006456/1, BB/W006456/1)
- License Information
-
More Information
Article History
Received: 26 February 2024
Accepted: 14 October 2024
First Online: 26 October 2024
Declarations
:
: HD and MG are employees and stockholders of Enterprise Therapeutics, which has previously developed TMEM16A modulators. ED, ENH, SL, RC, Ch, PM, RKG, ISR and DJT declare no competing interests.
